McKesson Corporation Announces Offer to Purchase Up to $1,100,000,000 Combined Purchase Price of Outstanding 6.000% Notes due 2041, 7.650% Debentures due 2027, 4.883% Notes due 2044, 4.750% Notes due 2021 and 7.500% Notes due 2019

Release Date: Wednesday, February 7, 2018 3:02 am CST

Terms:

SAN FRANCISCO – McKesson Corporation (NYSE: MCK) (the “Company”) today announced the commencement of a cash tender offer to purchase up to $1,100,000,000 (subject to increase, the “Tender Cap”) combined aggregate purchase price (the “Offer”) of its outstanding 6.000% Notes due 2041 (the “6.000% Notes”), 7.650% Debentures due 2027 (the “7.650% Debentures”), 4.883% Notes due 2044 (the “4.883% Notes”), 4.750% Notes due 2021 (the “4.750% Notes”) and 7.500% Notes due 2019 (the “7.500% Notes” and together with the 6.000% Notes, the 7.650% Debentures, the 4.883% Notes and the 4.750% Notes, the “Notes”, and each, a “series” of Notes), at purchase prices determined based on the yield to maturity of the applicable U.S. Treasury reference security specified in the table below plus the applicable Fixed Spread, as further described in the Company’s Offer to Purchase (as defined below).

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>CUSIP / ISIN Numbers</th>
<th>Principal Amount Outstanding</th>
<th>Acceptance Priority Level</th>
<th>Fixed Spread (basis points)</th>
<th>UST Reference Security</th>
<th>Bloomberg Reference Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.000% Notes due 2041</td>
<td>58155QAE3 / US58155QAE35</td>
<td>$500,000,000</td>
<td>1</td>
<td>127 bps</td>
<td>2.75% due November 15, 2047</td>
<td>PX1</td>
</tr>
<tr>
<td>7.650% Debentures due 2027</td>
<td>581557AM7 / US581557AM75</td>
<td>$175,000,000</td>
<td>2</td>
<td>105 bps</td>
<td>2.25% due November 15, 2027</td>
<td>PX1</td>
</tr>
<tr>
<td>4.883% Notes due 2044</td>
<td>581557 BC8 / US581557BC84</td>
<td>$800,000,000</td>
<td>3</td>
<td>120 bps</td>
<td>2.75% due November 15, 2047</td>
<td>PX1</td>
</tr>
<tr>
<td>4.750% Notes due 2021</td>
<td>58155QAD5 / US58155QAD51</td>
<td>$600,000,000</td>
<td>4</td>
<td>30 bps</td>
<td>2.25% due February 15, 2021</td>
<td>PX1</td>
</tr>
<tr>
<td>7.500% Notes due 2019</td>
<td>581557 AX3 / US581557AX31</td>
<td>$350,000,000</td>
<td>5</td>
<td>50 bps</td>
<td>0.75% due February 15, 2019</td>
<td>PX4</td>
</tr>
</tbody>
</table>

The Offer will expire at 11:59 p.m., New York City time, on March 7, 2018, unless extended or earlier terminated by the Company, with respect to any or all series of Notes (such date and time, as the same may be extended or earlier terminated, with respect to any or all series, the “Expiration Time”). Holders must validly tender and not properly withdraw their Notes at or prior to 5:00 p.m., New York City time, on February 21, 2018, unless extended by the Company, with respect to any or all series of Notes (such date and time, the “Early Tender Time”) in order to be eligible to receive the Full Tender Offer Consideration (defined below), which includes an early tender payment of $50 per $1,000 principal amount of Notes (the “Early Tender Payment”). Holders that validly tender their Notes after the Early Tender Time and at or prior to the Expiration Time will not be eligible to receive the Early Tender Payment and will only be eligible to
receive the Full Tender Offer Consideration minus the Early Tender Payment (the “Late Tender Offer Consideration”). In each case, Holders that validly tender Notes that are accepted for purchase by the Company will receive accrued and unpaid interest from, and including, the last interest payment date for their tendered Notes to, but not including, the settlement date for such Notes, in each case rounded to the nearest cent (“Accrued Interest”). Notes validly tendered may be withdrawn at any time on or prior to 5:00 p.m., New York City time, on February 21, 2018, with respect to any or all series of Notes (such date and time, as the same may be extended, the “Withdrawal Deadline”), unless extended by the Company, but not thereafter. The Depositary Trust Company and any broker, dealer, commercial bank, trust company or other nominee that holds the Notes may have earlier deadlines for tendering Notes pursuant to the Offer than the Early Tender Time or the Expiration Time.

The Company currently intends to redeem some or all of the 7.500% Notes that remain outstanding following the consummation of the Offer. Any such redemption would be made in accordance with the terms of the indenture governing the 7.500% Notes, which provides for a redemption price equal to the greater of (i) 100% of their principal amount and (ii) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on a semiannual basis at the Treasury Rate (as such term is defined in the 7.500% Notes) plus 50 basis points, plus accrued and unpaid interest to the date of redemption. The redemption price has not yet been determined and it is possible that the redemption price will be less or more than the applicable Full Tender Offer Consideration and/or the applicable Late Tender Offer Consideration for the 7.500% Notes in the Offer. However, the Company is not obligated to undertake any such redemption, and there can be no assurance that the Company will redeem any 7.500% Notes that remain outstanding after consummation of the Offer or of the timing of, or amount of any 7.500% Notes subject to, any such redemption.

The terms and conditions of the Offer are described in the offer to purchase, dated February 7, 2018 (the “Offer to Purchase”), and the related letter of transmittal (the “Letter of Transmittal” and, together with the Offer to Purchase, the “Offer Documents”).

Tendered Notes will be accepted in the order of the acceptance priority level for such series (in numerical priority order) as set forth in the table above, with 1 being the highest acceptance priority level, and based on whether the Notes are tendered at or before the Early Tender Time or after the Early Tender Time, as described in the Offer to Purchase. Notwithstanding the acceptance priority level, if any Notes are purchased in the Offer, Notes tendered at or prior to the Early Tender Time will be accepted for purchase in priority to Notes tendered after the Early Tender Time and at or prior to the Expiration Time. Accordingly, if the Tender Cap is reached in respect of tenders made at or prior to the Early Tender Time, no Notes of any series tendered after the Early Tender Time (regardless of acceptance priority level) will be accepted for purchase, unless we increase the Tender Cap. Under certain circumstances, the Company will accept tendered Notes of one or more of the series on a pro rata basis as further described in the Offer to Purchase. The Company reserves the right, but is not obligated, to increase the Tender Cap.

The Offer is subject to the satisfaction or waiver of certain conditions, including a financing condition, specified in the Offer to Purchase. Under these conditions and as more fully described in the Offer to Purchase, the Company expressly reserves its right, but is not obligated, with respect to any or all series of Notes, to extend the Offer at any time and may amend or terminate the Offer if, before such time as any Notes have been accepted for payment pursuant to the Offer, any condition of the Offer is not satisfied or, where applicable, waived.

The “Full Tender Offer Consideration” payable for the Notes will be a price per $1,000 principal amount of the Notes equal to an amount that would reflect, as of the date of purchase, a yield to the par call date (or, if such Notes do not have a par call date, the maturity date) of the applicable series of Notes (which is September 1, 2040 for the 6.000% Notes, March 1, 2027 for the 7.650% Debentures, September 15, 2043 for the 4.883% Notes, December 1, 2020 for the 4.750% Notes and February 15, 2019 for the 7.50% Notes) equal to the sum of (i) the Reference Yield for the applicable series of Notes, plus (ii) the applicable Fixed Spread. The Early Tender Payment is included in the amount of Full Tender Offer Consideration. See Schedule A to the Offer to Purchase for the formula to be used in determining the Full Tender Offer Consideration for the Notes.

If the Tender Cap is reached in respect of tenders made at or prior to the Early Tender Time, Notes validly tendered at or prior to the Early Tender Time will be subject to acceptance on a prorata basis, if the Tender Cap is not reached in respect of tenders made at or prior to the Early Tender Time, but is reached in respect of tenders made at or prior to the Expiration Time, Notes validly tendered after the Early Tender Time and at or prior to the Expiration Time will be subject to acceptance on a prorata basis.

The Company may, but it is not obligated, to elect following the Early Tender Time and prior to the Expiration Time to accept the Notes validly tendered at or prior to the Early Tender Time provided that all conditions to the Offer, including the financing condition, have been satisfied or waived by the Company. The Company may then settle such Notes at such time or promptly thereafter (such date of settlement, which is expected to be February 23, 2018 and is subject to change without notice, the “Early Settlement Date”). The “Final Settlement Date” is the date that the Company settles all Notes accepted for purchase and not previously settled on the Early Settlement Date, if any, and the Company expects such date to be one business day following the Expiration Time. The Company refers to each of the Early Settlement Date and the Final Settlement Date as a “Settlement Date.” Capitalized terms used in this press release and not defined herein have the meanings given to them in the Offer to Purchase.

Goldman Sachs & Co. LLC, BofA Merrill Lynch, and J.P. Morgan are acting as dealer managers for the Offer and HSBC and Wells Fargo Securities are acting as co-dealer managers for the Offer. For additional information regarding the terms of the Offer, please contact: Goldman Sachs & Co. LLC toll-free at (800) 828-3182 or collect at (212) 902-6595, BofA Merrill Lynch toll-free
at (888) 292-0070 or collect at (980) 387-3907 or J.P. Morgan toll-free at (866) 834-4666 or collect at (212) 834-3260. Requests for the Offer Documents may be directed to D.F. King & Co., Inc., which is acting as the Tender Agent and Information Agent for the Offer, at (800) 290-6426 (toll-free) or by email at mck@dfking.com [1].

THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT AN OFFER OR SOLICITATION TO PURCHASE NOTES. THE OFFER IS BEING MADE SOLELY PURSUANT TO THE OFFER DOCUMENTS, WHICH SET FORTH THE COMPLETE TERMS OF THE OFFER THAT HOLDERS OF THE NOTES SHOULD CAREFULLY READ PRIOR TO MAKING ANY DECISION.

THE OFFER DOCUMENTS DO NOT CONSTITUTE AN OFFER OR SOLICITATION TO PURCHASE NOTES IN ANY JURISDICTION IN WHICH, OR TO OR FROM ANY PERSON TO OR FROM WHOM, IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION UNDER APPLICABLE SECURITIES OR BLUE SKY LAWS. IN ANY JURISDICTION IN WHICH THE SECURITIES, BLUE SKY OR OTHER LAWS REQUIRE THE OFFER TO BE MADE BY A LICENSED BROKER OR DEALER, THE OFFER WILL BE DEEMED TO BE MADE ON BEHALF OF THE COMPANY BY ONE OR MORE OF THE DEALER MANAGERS, IF ANY OF THE DEALER MANAGERS ARE LICENSED BROKERS OR DEALERS UNDER THE LAWS OF SUCH JURISDICTION, OR BY ONE OR MORE REGISTERED BROKERS OR DEALERS THAT ARE LICENSED UNDER THE LAWS OF SUCH JURISDICTION.

About McKesson Corporation

McKesson Corporation, currently ranked 5th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, our employees work every day to innovate and deliver opportunities that make our customers and partners more successful — all for the better health of patients. McKesson has been named the “Most Admired Company” [2] in the healthcare wholesaler category by FORTUNE, a “Best Place to Work” [3] by the Human Rights Campaign Foundation, and a top military-friendly company [4] by Military Friendly. For more information, visit www.mckesson.com [5].

Language: English

Ticker Slug:

Ticker: MCK
Exchange: NYSE


Links:
[1] mailto:mck@dfking.com